trending Market Intelligence /marketintelligence/en/news-insights/trending/3ywzccwdjbu4sojtzkg3vw2 content esgSubNav
In This List

NeuroVive licenses chemistry for inherited vision loss treatment

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


NeuroVive licenses chemistry for inherited vision loss treatment

Sweden's NeuroVive Pharmaceutical AB said it licensed chemistry for its Leber's hereditary optic neuropathy treatment to California-based BridgeBio Pharma LLC.

The deal, which has a total transaction value of about $60 million, covers a subset of succinate prodrug chemistry under NeuroVive's NVP015 clinical program. The amount includes research funding, milestone payments and royalties.

Leber's hereditary optic neuropathy, or LHON, is a genetic condition that causes loss of vision.

BridgeBio said it launched a unit, called Fortify Therapeutics, to further develop the chemistry it acquired for use as local treatment of LHON, with an initial financial commitment of $20 million.

NeuroVive said development of NVP015 for other mitochondrial disorders will continue.